Company Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States.
Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery.
The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021.
Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| IPO Date | Feb 13, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Dr. Brian M. Strem Ph.D. |
Contact Details
Address: 1371 East 2100 South Salt Lake City, Utah United States | |
| Website | https://www.kiorapharma.com |
Stock Details
| Ticker Symbol | KPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372514 |
| CUSIP Number | 49721T101 |
| ISIN Number | US49721T3095 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brian M. Strem Ph.D. | President, Chief Executive Officer & Director |
| Melissa Tosca CPA | Chief Financial Officer |
| Dr. Eric J. Daniels M.B.A., M.D. | Chief Development Officer |
| Dr. Stefan Sperl Ph.D. | Executive Vice President of CMC & Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 08, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 4 | Filing |